2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P991091
    COVA322 98%
    COVA322 is a bispecific TNF and IL-17A antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases.
    COVA322
  • HY-P991111
    Anti-Mouse TIGIT Antibody (10A7) 98%
    Anti-Mouse TIGIT Antibody (10A7) is a mouse IgG2 monoclonal antibody that targets TIGIT. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978).
    Anti-Mouse TIGIT Antibody (10A7)
  • HY-P991113
    Abazistobart 3002062-67-8 98%
    Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers.
    Abazistobart
  • HY-P991114
    Adezkibart 2921564-55-6 98%
    Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases.
    Adezkibart
  • HY-P991116
    Amdokitug 3012586-05-6 98%
    Amdokitug is an anti-IL17A human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Amdokitug
  • HY-P991118
    Arumakimig 3018901-76-0 98%
    Arumakimig is a bispecific humanized anti-IL-18 and anti-IL-1β antibody. Arumakimig can be used in anti-inflammatory research.
    Arumakimig
  • HY-P991121
    Baloncibart 2988795-75-9 98%
    Baloncibart is a human IgG4K antibody targeting NPR1. The corresponding isotype control is: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Baloncibart
  • HY-P991123
    Bocunebart 2984605-64-1 98%
    Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases.
    Bocunebart
  • HY-P991125
    Cenzestotug 3014361-58-8 98%
    Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
    Cenzestotug
  • HY-P991126
    Ciltistotug 3014361-59-9 98%
    Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
    Ciltistotug
  • HY-P991127
    Claseprubart 2922766-89-8 98%
    Claseprubart is a monoclonal antibody targeting human complement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases.
    Claseprubart
  • HY-P991129
    Crusekitug 2956768-50-4 98%
    Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
    Crusekitug
  • HY-P991134
    Elegrobart 2832924-76-0 98%
    Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease.
    Elegrobart
  • HY-P991138
    Firsekibart 2981430-39-9 98%
    Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease.
    Firsekibart
  • HY-P991142
    Isuventatug 2986317-23-9 98%
    Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy.
    Isuventatug
  • HY-P991144
    Lasrekibart 3021525-26-5 98%
    Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma.
    Lasrekibart
  • HY-P991146
    Lecankitug 2923284-76-6 98%
    Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis.
    Lecankitug
  • HY-P991150
    Ompekimig 2981477-39-6 98%
    Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis.
    Ompekimig
  • HY-P991152
    Oturkibart 2956767-43-2 98%
    Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis.
    Oturkibart
  • HY-P991156
    Rapaprutug 2994192-38-8 98%
    Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases.
    Rapaprutug
Cat. No. Product Name / Synonyms Application Reactivity